CNS Pharmaceuticals Statistics
Share Statistics
CNS Pharmaceuticals has 57.49M shares outstanding. The number of shares has increased by 417.27% in one year.
| Shares Outstanding | 57.49M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 13461.65% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 56.89M |
| Failed to Deliver (FTD) Shares | 1.80K |
| FTD / Avg. Volume | 0.01% |
Short Selling Information
The latest short interest is 1.14M, so 1.98% of the outstanding shares have been sold short.
| Short Interest | 1.14M |
| Short % of Shares Out | 1.98% |
| Short % of Float | 2.01% |
| Short Ratio (days to cover) | 0.04 |
Valuation Ratios
The PE ratio is -0.25 and the forward PE ratio is -0.33.
| PE Ratio | -0.25 |
| Forward PE | -0.33 |
| PS Ratio | 0 |
| Forward PS | 0.2 |
| PB Ratio | -1.07 |
| P/FCF Ratio | -0.34 |
| PEG Ratio | n/a |
Enterprise Valuation
CNS Pharmaceuticals Inc. has an Enterprise Value (EV) of -.
| EV / Earnings | null |
| EV / Sales | null |
| EV / EBITDA | null |
| EV / EBIT | null |
| EV / FCF | null |
Financial Position
The company has a current ratio of 0.26, with a Debt / Equity ratio of -0.07.
| Current Ratio | 0.26 |
| Quick Ratio | 0.26 |
| Debt / Equity | -0.07 |
| Total Debt / Capitalization | -7.28 |
| Cash Flow / Debt | -47.01 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is 4.25% and return on capital (ROIC) is 456.64%.
| Return on Equity (ROE) | 4.25% |
| Return on Assets (ROA) | -11.08% |
| Return on Capital (ROIC) | 456.64% |
| Revenue Per Employee | 0 |
| Profits Per Employee | -6.28M |
| Employee Count | 3 |
| Asset Turnover | 0 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -99.88% in the last 52 weeks. The beta is 1.05, so CNS Pharmaceuticals 's price volatility has been higher than the market average.
| Beta | 1.05 |
| 52-Week Price Change | -99.88% |
| 50-Day Moving Average | 0.12 |
| 200-Day Moving Average | 4.9 |
| Relative Strength Index (RSI) | 40.06 |
| Average Volume (20 Days) | 15.40M |
Income Statement
In the last 12 months, CNS Pharmaceuticals had revenue of $0 and earned -$18.85M in profits. Earnings per share was $-251.35.
| Revenue | 0 |
| Gross Profit | -4.13K |
| Operating Income | -18.87M |
| Net Income | -18.85M |
| EBITDA | -18.86M |
| EBIT | - |
| Earnings Per Share (EPS) | -251.35 |
Balance Sheet
The company has $548.72K in cash and $300.81K in debt, giving a net cash position of $247.91K.
| Cash & Cash Equivalents | 548.72K |
| Total Debt | 300.81K |
| Net Cash | 247.91K |
| Retained Earnings | -69.57M |
| Total Assets | 7.41M |
| Working Capital | 3.33M |
Cash Flow
In the last 12 months, operating cash flow was -$14.14M and capital expenditures -$3.90K, giving a free cash flow of -$14.14M.
| Operating Cash Flow | -14.14M |
| Capital Expenditures | -3.90K |
| Free Cash Flow | -14.14M |
| FCF Per Share | -188.59 |
Margins
Gross margin is 0%, with operating and profit margins of 0% and 0%.
| Gross Margin | 0% |
| Operating Margin | 0% |
| Pretax Margin | 0% |
| Profit Margin | 0% |
| EBITDA Margin | n/a% |
| EBIT Margin | n/a% |
| FCF Margin | n/a% |
Dividends & Yields
CNSP does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -251350% |
| FCF Yield | -246.78% |
Analyst Forecast
The average price target for CNSP is $0.5, which is 400% higher than the current price. The consensus rating is "Buy".
| Price Target | $0.5 |
| Price Target Difference | 400% |
| Analyst Consensus | Buy |
| Analyst Count | 1 |
Stock Splits
The last stock split was on Jun 5, 2024. It was a backward split with a ratio of 1:50.
| Last Split Date | Jun 5, 2024 |
| Split Type | backward |
| Split Ratio | 1:50 |
Scores
| Altman Z-Score | -21.49 |
| Piotroski F-Score | 4 |